S&P 500   3,807.43 (-1.10%)
DOW   30,637.51 (-0.97%)
QQQ   325.53 (-0.93%)
AAPL   143.32 (+0.11%)
MSFT   239.16 (+2.94%)
FB   277.46 (-1.63%)
GOOGL   1,853.15 (-2.87%)
AMZN   3,301.18 (-0.75%)
TSLA   885.16 (+0.23%)
NVDA   525.09 (-2.29%)
BABA   262.90 (-1.14%)
CGC   36.23 (+2.00%)
GE   10.86 (-3.81%)
MU   76.79 (-3.42%)
AMD   89.70 (-5.29%)
NIO   59.08 (-2.04%)
T   29.98 (+0.77%)
F   10.93 (-2.32%)
ACB   10.80 (+1.22%)
BA   195.43 (-3.28%)
DIS   163.36 (-3.66%)
NFLX   545.83 (-2.87%)
GILD   65.40 (-1.95%)
S&P 500   3,807.43 (-1.10%)
DOW   30,637.51 (-0.97%)
QQQ   325.53 (-0.93%)
AAPL   143.32 (+0.11%)
MSFT   239.16 (+2.94%)
FB   277.46 (-1.63%)
GOOGL   1,853.15 (-2.87%)
AMZN   3,301.18 (-0.75%)
TSLA   885.16 (+0.23%)
NVDA   525.09 (-2.29%)
BABA   262.90 (-1.14%)
CGC   36.23 (+2.00%)
GE   10.86 (-3.81%)
MU   76.79 (-3.42%)
AMD   89.70 (-5.29%)
NIO   59.08 (-2.04%)
T   29.98 (+0.77%)
F   10.93 (-2.32%)
ACB   10.80 (+1.22%)
BA   195.43 (-3.28%)
DIS   163.36 (-3.66%)
NFLX   545.83 (-2.87%)
GILD   65.40 (-1.95%)
S&P 500   3,807.43 (-1.10%)
DOW   30,637.51 (-0.97%)
QQQ   325.53 (-0.93%)
AAPL   143.32 (+0.11%)
MSFT   239.16 (+2.94%)
FB   277.46 (-1.63%)
GOOGL   1,853.15 (-2.87%)
AMZN   3,301.18 (-0.75%)
TSLA   885.16 (+0.23%)
NVDA   525.09 (-2.29%)
BABA   262.90 (-1.14%)
CGC   36.23 (+2.00%)
GE   10.86 (-3.81%)
MU   76.79 (-3.42%)
AMD   89.70 (-5.29%)
NIO   59.08 (-2.04%)
T   29.98 (+0.77%)
F   10.93 (-2.32%)
ACB   10.80 (+1.22%)
BA   195.43 (-3.28%)
DIS   163.36 (-3.66%)
NFLX   545.83 (-2.87%)
GILD   65.40 (-1.95%)
S&P 500   3,807.43 (-1.10%)
DOW   30,637.51 (-0.97%)
QQQ   325.53 (-0.93%)
AAPL   143.32 (+0.11%)
MSFT   239.16 (+2.94%)
FB   277.46 (-1.63%)
GOOGL   1,853.15 (-2.87%)
AMZN   3,301.18 (-0.75%)
TSLA   885.16 (+0.23%)
NVDA   525.09 (-2.29%)
BABA   262.90 (-1.14%)
CGC   36.23 (+2.00%)
GE   10.86 (-3.81%)
MU   76.79 (-3.42%)
AMD   89.70 (-5.29%)
NIO   59.08 (-2.04%)
T   29.98 (+0.77%)
F   10.93 (-2.32%)
ACB   10.80 (+1.22%)
BA   195.43 (-3.28%)
DIS   163.36 (-3.66%)
NFLX   545.83 (-2.87%)
GILD   65.40 (-1.95%)
Log in
NASDAQ:TGTX

TG Therapeutics News Headlines

$48.61
-1.40 (-2.80 %)
(As of 01/27/2021 10:51 AM ET)
Add
Compare
Today's Range
$48.00
Now: $48.61
$49.88
50-Day Range
$29.62
MA: $50.17
$54.90
52-Week Range
$6.34
Now: $48.61
$56.74
Volume29,821 shs
Average Volume1.65 million shs
Market Capitalization$6.39 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.28

Headlines

TG Therapeutics (NASDAQ TGTX) News Headlines Today

Source:
SourceHeadline
TG Therapeutics (NASDAQ:TGTX) Lifted to Hold at Zacks Investment ResearchTG Therapeutics (NASDAQ:TGTX) Lifted to Hold at Zacks Investment Research
marketbeat.com - January 23 at 6:47 AM
TG Therapeutics (NASDAQ:TGTX) Downgraded by BidaskClub to "Buy"TG Therapeutics (NASDAQ:TGTX) Downgraded by BidaskClub to "Buy"
marketbeat.com - December 31 at 2:07 AM
$40,000.00 in Sales Expected for TG Therapeutics, Inc. (NASDAQ:TGTX) This Quarter$40,000.00 in Sales Expected for TG Therapeutics, Inc. (NASDAQ:TGTX) This Quarter
americanbankingnews.com - January 26 at 3:26 AM
TG Therapeutics (NASDAQ:TGTX) & Acusphere (OTCMKTS:ACUS) Critical ContrastTG Therapeutics (NASDAQ:TGTX) & Acusphere (OTCMKTS:ACUS) Critical Contrast
americanbankingnews.com - January 25 at 9:22 PM
TG Therapeutics (NASDAQ:TGTX)  Shares Down 5.3% TG Therapeutics (NASDAQ:TGTX) Shares Down 5.3%
americanbankingnews.com - January 21 at 8:02 PM
TG Therapeutics (NASDAQ:TGTX) PT Raised to $78.00 at HC WainwrightTG Therapeutics (NASDAQ:TGTX) PT Raised to $78.00 at HC Wainwright
americanbankingnews.com - January 19 at 2:49 PM
TG Therapeutics to Participate in the B. Riley Securities Oncology Investor ConferenceTG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference
finance.yahoo.com - January 15 at 9:50 AM
High Flying TG Therapeutics Needs a Period of ConsolidationHigh Flying TG Therapeutics Needs a Period of Consolidation
finance.yahoo.com - January 14 at 5:07 PM
TG Therapeutics CEO on developing treatments for patients with multiple sclerosisTG Therapeutics CEO on developing treatments for patients with multiple sclerosis
msn.com - January 13 at 7:50 PM
TG Therapeutics CEO talks journey to becoming a commercial pharmaceutical companyTG Therapeutics CEO talks journey to becoming a commercial pharmaceutical company
cnbc.com - January 13 at 7:50 PM
TG Therapeutics (NASDAQ:TGTX) Sets New 12-Month High at $56.59TG Therapeutics (NASDAQ:TGTX) Sets New 12-Month High at $56.59
americanbankingnews.com - January 13 at 12:15 PM
TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceTG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 8 at 7:34 AM
FY2021 Earnings Estimate for TG Therapeutics, Inc. Issued By Jefferies Financial Group (NASDAQ:TGTX)FY2021 Earnings Estimate for TG Therapeutics, Inc. Issued By Jefferies Financial Group (NASDAQ:TGTX)
americanbankingnews.com - January 6 at 8:56 AM
Jefferies Financial Group Comments on TG Therapeutics, Inc.s FY2025 Earnings (NASDAQ:TGTX)Jefferies Financial Group Comments on TG Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:TGTX)
americanbankingnews.com - January 5 at 7:44 AM
Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock?Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock?
finance.yahoo.com - December 24 at 2:29 PM
Is TGTX A Good Stock To Buy According To Hedge Funds?Is TGTX A Good Stock To Buy According To Hedge Funds?
finance.yahoo.com - December 21 at 4:14 PM
TG Therapeutics Reaches Analyst Target PriceTG Therapeutics Reaches Analyst Target Price
nasdaq.com - December 17 at 2:50 PM
Thinking about trading options or stock in Moderna, Alibaba, TG Therapeutics, Tesla, or American Airlines?Thinking about trading options or stock in Moderna, Alibaba, TG Therapeutics, Tesla, or American Airlines?
marketwatch.com - December 10 at 6:35 PM
Stock Alert: TG Therapeutics Soars On Positive Data From Late Stage Studies Of UblituximabStock Alert: TG Therapeutics Soars On Positive Data From Late Stage Studies Of Ublituximab
nasdaq.com - December 10 at 6:35 PM
TG Therapeutics Soars on Positive Results for MS TreatmentTG Therapeutics Soars on Positive Results for MS Treatment
thestreet.com - December 10 at 6:35 PM
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple SclerosisTG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
finance.yahoo.com - December 10 at 7:31 AM
TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual MeetingTG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - December 7 at 3:56 PM
TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual MeetingTG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - December 7 at 3:56 PM
TG Therapeutics: Excellent, Multi-Modal OpportunityTG Therapeutics: Excellent, Multi-Modal Opportunity
seekingalpha.com - December 7 at 9:17 AM
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and ExpositionTG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition
finance.yahoo.com - December 3 at 8:32 AM
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in BloodTG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in Blood
finance.yahoo.com - December 2 at 5:23 PM
TG Therapeutics commences rolling U.S. application for doublet therapy for CLLTG Therapeutics commences rolling U.S. application for doublet therapy for CLL
seekingalpha.com - December 1 at 9:00 AM
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic LeukemiaTG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
finance.yahoo.com - December 1 at 9:00 AM
TG THERAPEUTICS DL -,001 (NKB2.DU)TG THERAPEUTICS DL -,001 (NKB2.DU)
uk.finance.yahoo.com - November 30 at 11:00 PM
TG Therapeutics to Participate in the 3rd Annual Evercore ISI HealthCONx ConferenceTG Therapeutics to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
finance.yahoo.com - November 30 at 7:32 AM
TG Therapeutics to Participate in the Jefferies Virtual London Healthcare ConferenceTG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 13 at 7:27 AM
Was The Smart Money Right About Loading Up On TG Therapeutics Inc (TGTX)?Was The Smart Money Right About Loading Up On TG Therapeutics Inc (TGTX)?
finance.yahoo.com - November 10 at 12:49 PM
TG Therapeutics EPS misses by $0.32, beats on revenue; outlookTG Therapeutics EPS misses by $0.32, beats on revenue; outlook
seekingalpha.com - November 9 at 8:05 PM
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial ResultsTG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
finance.yahoo.com - November 9 at 8:05 PM
TG Therapeutics (TGTX) Reports Q3 Loss, Lags Revenue EstimatesTG Therapeutics (TGTX) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 9 at 8:05 PM
TG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual MeetingTG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 4 at 3:38 PM
TG Therapeutics (TGTX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseTG Therapeutics (TGTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
finance.yahoo.com - November 3 at 5:33 PM
TG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and ExpositionTG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition
finance.yahoo.com - November 2 at 11:29 AM
TG Therapeuticss ublituximab/umbralisib combo Fast Trackd in U.S. for blood cancerTG Therapeutics's ublituximab/umbralisib combo Fast Track'd in U.S. for blood cancer
seekingalpha.com - October 21 at 12:35 PM
TG Therapeuticss ublituximab Fast Trackd in U.S. for CLLTG Therapeutics's ublituximab Fast Track'd in U.S. for CLL
seekingalpha.com - October 21 at 12:35 PM
TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic LeukemiaTG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia
finance.yahoo.com - October 21 at 12:35 PM
Look to Go Long TG Therapeutics on a PullbackLook to Go Long TG Therapeutics on a Pullback
finance.yahoo.com - October 21 at 12:35 PM
TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD1TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD1
bloomberg.com - October 1 at 11:39 PM
3 Biotech Stocks with STRONG Momentum3 Biotech Stocks with STRONG Momentum
stocknews.com - September 16 at 7:37 PM
Hedge Funds Can’t Stop Buying TG Therapeutics Inc (TGTX)Hedge Funds Can’t Stop Buying TG Therapeutics Inc (TGTX)
finance.yahoo.com - September 14 at 1:17 PM
TG Therapeutics IncTG Therapeutics Inc
reuters.com - August 31 at 12:49 AM
3 Monster Growth Stocks That Still Have Room to Run3 Monster Growth Stocks That Still Have Room to Run
finance.yahoo.com - August 30 at 9:47 AM
Analyzing TG Therapeutics's Unusual Options ActivityAnalyzing TG Therapeutics's Unusual Options Activity
finance.yahoo.com - August 17 at 7:34 PM
Analyzing TG Therapeuticss Unusual Options ActivityAnalyzing TG Therapeutics's Unusual Options Activity
benzinga.com - August 17 at 2:25 PM
TG Therapeutics Umbralisib Development, And Other News: The Good, Bad And Ugly Of BiopharmaTG Therapeutics Umbralisib Development, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - August 14 at 5:31 PM
Why TG Therapeutics Is Trading Higher TodayWhy TG Therapeutics Is Trading Higher Today
benzinga.com - August 13 at 6:00 PM
FDA accepts TG Therapeutics umbralisib application, action date February 2021FDA accepts TG Therapeutics' umbralisib application, action date February 2021
seekingalpha.com - August 13 at 1:00 PM
This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.